A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

by | Dec 10, 2025 | Clinical Trials | 0 comments

​ Conditions: Advanced/Metastatic Solid Tumors; NSCLC

Interventions: Drug: HLX37-Dose1; Drug: HLX37-Dose2; Drug: HLX37-Dose3; Drug: HLX37-Dose4

Sponsors: Shanghai Henlius Biotech

Active, not recruiting Conditions: Advanced/Metastatic Solid Tumors; NSCLC
Interventions: Drug: HLX37-Dose1; Drug: HLX37-Dose2; Drug: HLX37-Dose3; Drug: HLX37-Dose4
Sponsors: Shanghai Henlius Biotech
Active, not recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *